House Committee Advances Medicare Alzheimer's Test Coverage
The proposed bill would expand Medicare coverage for Alzheimer’s blood tests to help at-risk seniors access early detection.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Should Medicare cover new blood tests for the early detection of Alzheimer's disease?
On September 16, 2026, the House Ways and Means Committee passed the Alzheimer's Screening and Prevention Act to facilitate Medicare coverage for diagnostic blood tests. This move could provide millions of seniors with a less invasive alternative to traditional spinal taps or amyloid PET scans.
Why it matters
Current Medicare policy often restricts payment for preventive testing, creating barriers to early diagnosis for those at elevated risk. This legislation aims to bridge that gap by establishing a clear path for covering the new generation of blood-based Alzheimer's tests.
The bill follows the FDA's May 2025 clearance of the first Alzheimer's blood test. Legislators are evaluating whether to mandate Medicare coverage for these tests specifically for individuals identified as being at elevated risk.
The players
U.S. House Ways and Means Committee
The congressional committee responsible for overseeing tax and Medicare-related legislation.
Food and Drug Administration
The federal agency responsible for protecting public health by regulating medical devices and diagnostic tests.
The details
Alzheimer's blood tests are designed to detect biomarkers associated with the disease, offering a diagnostic alternative to invasive spinal taps or costly amyloid PET scans. Under the proposed bill, Medicare coverage for these tests would function transitionally while a formal, permanent coverage determination process is completed. The measure is specifically aimed at screening patients who present with elevated risk factors for cognitive decline.
Timeline
May 2025: The FDA cleared the first Alzheimer's blood test for clinical use.
September 15, 2026: The House Energy and Commerce Subcommittee held a hearing on the proposed legislation.
September 16, 2026: The House Ways and Means Committee voted unanimously to pass the bill.
Health Landscape
This legislation marks a departure from standard Medicare preventive services guidelines by explicitly targeting blood-based biomarker diagnostics. It reflects an evolving approach to Alzheimer's care that favors early, accessible detection methods over traditional, more invasive neurological assessments.
If you are concerned about cognitive decline, these proposed changes may eventually lower the cost of diagnostic blood work and improve access to early screening. Discuss the current availability of cognitive testing and your individual risk factors with your primary care physician.
The takeaway
Early detection of Alzheimer's is shifting toward less invasive diagnostic technologies like blood tests. If you are at elevated risk for cognitive changes, ask your doctor about the current status of diagnostic options and which screening methods are most appropriate for your health profile.
Further reading
Learn more about the latest diagnostic tools and care guidelines in the United States Alzheimer’s section.
Source note: This article includes information reported by Atlanta Magazine.
Live Poll
Should Medicare cover new blood tests for the early detection of Alzheimer's disease?
